Skip to main content
2024 Guide to Patient Support Services

Sanofi

2024 PSS Guide

Sanofi CareASSIST Patient Support Services

Sanofi offers the CareASSIST Program to assist patients prescribed certain Sanofi medications (Table).

CareASSIST

This program offers several patient support resources, including financial assistance through the CareASSIST Copay Program and the CareASSIST Patient Assistance Program, and additional resource support through CareASSIST Care Managers.

CareASSIST Copay Program

Eligible patients with commercial insurance may pay as little as $0 for their Sanofi medication, including any product-specific copay and coinsurance—up to $25,000 in assistance per year.

To apply for the CareASSIST Copay Program, call 833-930-2273 or complete the enrollment form found at the CareASSIST Copay Program.

CareASSIST Patient Assistance Program

Patients who meet program requirements can receive their medication at no cost through the CareASSIST Patient Assistance Program.

To apply for the CareASSIST Patient Assistance Program, call 833-930-2273 or complete the enrollment form found at the CareASSIST Patient Assistance Program.

CareASSIST Care Managers

CareASSIST Care Managers may be able to assess insurance coverage and identify support options for your patients.

To learn more or to enroll your patient in CareASSIST, please call 833-930-2273 or complete the enrollment form found at the CareASSIST Care Managers.

TABLE Sanofi Supportive Care Drugs

Drugs
Indications
Patient support programs

Drug
Elitek (rasburicase)
Indications
Single course of treatment for the initial management of plasma uric acid levels in patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid
Patient support programs

Drug
Jevtana (cabazitaxel)
Indications
Treatment of patients with metastatic castration-resistant prostate cancer, in combination with prednisone, after a docetaxel-containing regimen
Patient support programs

Drug
Sarclisa (isatuximab-irfc) injection
Indications
Patient support programs

Sarclisa (isatuximab-irfc) injection Indications

In combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received ≥2 therapies including lenalidomide and a proteasome inhibitor; in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy